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Summary: The potential importance of the non^enzymatic glycation of low density lipoproteins (LDL) in
atherogenesis and in the accelerated atherosclerosis associated with diabetes is well recognized. However, it
has been difficult to evaluate LDL glycation in the clinical setting because of the lack of suitable methods.
To approach this problem, we produced monoclonal antibodies, designated ES 12, that recognize glycated
apolipoprotein B epitopes in the LDL complex in human plasma. Here we report the use of these antibodies
in a competitive enzyme-linked imniunosorbent assay (ELISA) to measure glycated LDL concentrations in
plasma from non-diabetic and diabetic subjects. In this assay, glycated LDL in the soluble phase inhibits
binding of the ES 12 antibody to glycated LDL immobilized to microtitre wells, whereas other glycated
proteins and non-glycated LDL do not compete. A linear dose-response relationship for 10 —125 ng glycated
LDL per well allows the construction of standard curves, from which the concentration of glycated LDL in
human plasma can be determined. The mean concentration of glycated LDL in samples from non-diabetic
subjects was 21.8 + 0.9 mg/1, increasing to 40.8 ± 2.6 mg/1 in samples from patients with type II diabetes,
comprising 1.9—4.8% and 3.2—14.8%, respectively, of total apolipoprotein B. Glycated LDL concentrations
in samples from diabetic patients correlated positively and significantly with other indices of glycaemic status.
The results indicate that circulating glycated LDL, which may have diagnostic and pathophysiologic impor-
tance, is increased in diabetes with attendant hyperglycaemia. The results further indicate that the described
monoclonal antibody^based competitive ELISA affords a simple and reproducible method for quantitative
measurement of glycated LDL.
Introduction · · . , , . ι · ι -
siderable interest, because it has been implicated in
Non-enzymatic glycation is a condensation reaction the premature and severe atherosclerosis associated
between glucose and reactive protein amino groups with diabetes mellitus, and LDL glycation is one of
at the NH2-terminus or e-amino groups of lysine the post-secretory modifications believed to affect its
residues. In diabetic subjects, hyperglycaemia pro- atherogenic potential. For example, internalization
motes increased non-enzymatic glycation of circulat- and degradation by cultured fibroblasts of LDL from
ing and tissue proteins, thereby allowing assessment patients with insulin-dependent diabetes and poor
of integrated glycaemic control through determina- metabolic control is decreased, compared with that
tion of glycohaemoglobin and glyco lbumin concen- of LDL isolated from normal subjects or from pa-
trations, and also providing insight into pathogenetic tients with insulin-dependent diabetes and good met-
mechanisms associated with chronic complications of abolic control (1). Glycation of LDL diminishes the
diabetes. The non-enzymatic glycation of apolipopro- high affinity LDL receptor-mediated uptake and de-
teinB, the principal protein of the cholesterol-carrying gradation of LDL (2—7), and may promote inter-
low density lipoproteins (LDL), has generated con- nalization by alternative receptors of monocyte-mac-
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rophages that give rise to foam cells (8-12). Addi-
tionally, glycation alters the rate of clearance of LDL
in vivo, and may interfere with intracellular handling
of cholesterol and regulation of its synthesis (4, 13,
16). Further, non-enzymatically glycated proteins may
have accelerated rates of free radical production (17,
18), which could increase lipid peroxidation and
thereby enhance LDL atherogenicity through for-
mation of modified apolipoprotein B adducts that are
recognized and internalized by the classic macrophage
scavenger receptor (19-21). Some (22, 23) but not
all (24) investigators propose that glucose auto-oxi-
dation and sequential modification by glycation and
oxidation ("glycoxidation") contribute to increased
atherogenesis in diabetes.
Although the potential importance of elevated gly-
cated LDL concentrations in atherogenesis is well
recognized, suitable methods for quantitative analysis
of plasma glycated LDL have been lacking. To ap-
proach this problem, we established hybridomas se-
creting monoclonal antibodies that recognize glycated
epitopes residing in the apolipoprotein B of the LDL
complex but not in other plasma proteins (25). These
antibodies, which have been designated ES 12, react
on Western blotting and in immunoassay with poly-
peptides in the LDL complex in human plasma; the
polypeptides show co-identity with apolipoprotein B
on separate immunoblotting when reacted with apo-
lipoprotein B-specific monoclonal antibodies. In the
present study, we report measurement of glycated
LDL in human plasma with a competitive enzyme-
linked immunosorbent assay (ELISA) that employs
the ES12 monoclonal antibodies. Results are ex-
pressed as μg (glycated) apolipoprotein B equivalents,
and can be converted to the fraction (percent) of
apolipoprotein B that is glycated by dividing by the
total apolipoprotein B concentration, measured in-
dependently, in a sample. With this assay, the con-
centration of glycated LDL in plasma obtained from
patients with type II diabetes was approximately one
and a half fold greater than that found in samples
from non-diabetic individuals, and correlated with
other indices of integrated glycaemic status.
Materials and Methods
Preparation of glycated proteins
Glycated LDL was isolated from human LDL (Sigma Chem
Co.) by chromatography on a column of phenylboronate aga-
rose, which binds cw-diol groups of sugars. Some LDL prep-
arations were chromatographed without pretreatment, while
others were first subjected to glycation in vitro. LDL prepa-
rations were first examined for contaminating immunoglobulins
which, if present, were removed by immunoadsorption with
anti-human immunoglobulin polyclonal antibody. After equil-
ibration and washing, the glycated protein was eluted from the
phenylboronate agarose column with 100 mmoi/1 sofbitol (26).
The amount of glycated LDL in the eluant was determined as
apolipoprotein B equivalents, measured as micrograms apoli-
poprotein B by competitive immunoassay using a murine mono-
clonal antibody B36 (see below) which had been raised against
purified human apolipoprotein B-10p (Scripps Laboratories,
San Diego, CA). In vitro glycation was performed by incubating
LDL for five days at room temperature under a nitrogen
atmosphere in 0.15 mol/1 saline/1 mmol/1 EDTA, pH 7.4, con-
taining 5 g/1 glucose, followed by dialysis against saline/EDTA
to remove unbound glucose. Unretained material from the
loading of the phenylboronate agarose column was used as a
source of non-glycated protein.
Glycated albumin was purified from human plasma by sequen-
tial chromatography on Affirgel blue and phenylboronate aga-
rose as described (27). Glycated haemoglobin was purified from
lysates of human erythrocytes by sequential ion exchange
(BioRex 70) and affinity (phenylboronate agarose) chromato-
graphy (26).
Generation of monoclonal antibodies
The production and partial characterization of the ES 12 mono-
clonal antibodies to glycated LDL has been described (25). In
brief, male BALB/c mice were immunized by intraperitoneal
injection of glycated apolipoprotein B, which was prepared by
incubation of purified apolipoprotein B with 5 g/1 glucose in
saline/EDTA for three days, followed by dialysis and affinity
chromatography on phenylboronate agarose. Spleen cells from
immunized animals were fused with SP 2/0 myeloma cells and
hybridoma colonies were established according to standard
techniques (28). The resulting colonies, which displayed pref-
erential binding activity to glycated apolipoprotein B and to
glycated LDL in direct ELISA, were cloned at least three times
by limiting dilution. The colony designated ESI2 secreted an-
tibodies discriminating between glycated versus non-glycated
apolipoprotein B and exhibiting the same discrimination for
glycated versus non-glycated LDL. On immunoblotting and in
direct ELISA these antibodies reacted with glycated epitopes
residing within the apolipoprotein B of the LDL complex, did
not react with non-glycated LDL, and did not react with other
circulating proteins, whether glycated or not (25). Metal-cata-
lysed oxidation of glycated LDL abolished reactivity with the
antibodies, indicating that the recognized epitope is glucose-
modified and not a lipid oxidation or glycoxidation product
(25). The ES 12 antibodies, shown by Ouchterlony diffusion to
be of the IgGi class, were purified from culture supernatant or
from mouse ascites fluid by protein G affinity chromatography,
and used for development of a competitive ELISA for meas-
uring glycated LDL in human plasma.
Antibodies to the apolipoprotein B were generated in male
BALB/c mice following the schedule described above, using
apolipoprotein B-100 (Scripps Laboratories) as immunogen.
The colony designated B36 secreted antibodies recognizing pu-
rified apolipoprotein B-100 (Scripps) and apolipoprotein B in
LDL (Sigma Chem Co) and unreactive with apolipoprotein Α-
Ι or high density lipoprotein (Sigma) (25). The B36 antibodies
do not discriminate between glycated versus non-glycated apo-
lipoprotein B. The B36 antibodies, which are of the IgGi class,
were purified from mouse ascites fluid by protein G affinity
chromatography and used for development of the competitive
ELISA for measuring apolipoprotein B.
Competitive ELISA for glycated LDL
.Plastic microtitre wells (Nunc Polysorb) were coated with an-
tigen (250 ng protein per well) by iqcubation for 18 hours at
room temperature in carbonate-bicarbonate coupling buffer,
pH 8.5. After washing to remove unbound material, wells were
blocked with 0.1 mol/1 Tris HC1, pH 7.5, containing fetal bovine
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serum, volume fraction 0.1, and stored at 4°C in the same
buffer until use. The wash buffer contained 0.05 mol/1 triethyl-
amine, 0.5 g/1 Tween-20 in saline, pH 7.2. To initiate the assay,
the plates are washed and standard or sample in 50 μΐ of assay
buffer (0.1 mol/1 Tris HCl, pH 7.5, containing fetal bovine
serum, volume fraction 0.1, and 2 g/1 Tween-20), is added.
Monoclonal antibody ESI2 diluted in buffer (3 μg per well) is
added immediately thereafter, and the plates are incubated at
room temperature for 1 hour. After washing, horse radish
peroxidase-conjugatcd goat anti-mouse IgG (1 :2000 in 0.1
mol/1 Tris containing fetal bovine serum, volume fraction 0.1)
is added and incubation proceeds for 1 hour. The plates are
washed again, followed by addition of substrate (TMBIue mi-
crowell peroxidase system) and stopper (1 mol/1 H2SO4). Ab-
sorbances are read at 450 nm.
Analysis
Apolipoprotein B was measured by competitive ELISA, in
which apolipoprotein B was immobilized onto plastic microtitre
wells (Costar) by overnight incubation at room temperature in
carbonate coating buffer, followed by washing, blocking and
storage as above. After washing, the assay was initiated by
addition of standard or sample in assay buffer followed by the
B36 antibody (1 μg per well), and the plates were incubated for
30 minutes at room temperature. Development and detection
were accomplished with horseradish peroxidase conjugated goat
anti-mouse IgG and substrate, as described above. The assay
yields an inverse linear dose-response relationship between 0.25
and 2.0 μg of apolipoprotein B. The competitive ELISA for
apolipoprotein B was used to measure concentrations of apo-
lipoprotein Β in the glycated LDL preparations (for standard-
ization of the glycated LDL competitive assay), and in the
human plasma samples, allowing expression of results from the
glycated LDL assay s the percentage of total apolipoprotein
B that is glycated.
Results
The ES 12 monoclonal antibodies used in these exper-
iments recognize epitopes contained within high mo-
lecular mass polypeptides of purified glycated LDL;
identical bands were visualized when human plasma
was transferred to nitrocellulose after SDS gel elec-
trophoresis and immunoblotted with the ES 12 anti-
body (25). These polypeptide bands have been shown
to have co^-identity with apolipoprotein B by separate
immunoblotting with the B36 monoclonal antibody,
which was raised against apolipoprotein B-100 and
does not discriminate between glycated versus non-
glycated apolipoprotein B (25).
Glycated LDL added in the soluble phase with the
ESI2 monoclonal antibody competitively inhibited
binding of the antibody to glycated LDL immobilized
onto the microtitre wells. The phenylboronate aga-
rose-adsorbed fraction of unincubated LDL or glu-
cose-incubated LDL contained glycated LDL that
immunoreacted in competitive ELISA with the ES 12
antibody, whereas unretained material from the phen-
ylboronate agarose did not react (fig. 1). LDL gly-
cated in vitro exhibited immunoreactivity identical to
"in vivo" glycated LDL on Western blotting (not
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Fig. 1. Competitive immunoassay of glycated LDL
a) Experimental conditions: 250 ng of glycated LDL
(phenylboronate agarose-adsorbed fraction) immo-
bilized onto plastic microtitre wells were incubated
with variable amounts of candidate antigens and
ES 12 monoclonal antibody (3 μg per well) in the
soluble phase. Glycated LDL used for competition
was represented by phenylboronate agarose-ad-
sorbed protein in non-incubated (open circles, solid
line) or glucose-incubated (closed circles, dashed line)
material. Development and detection were with
horseradish peroxidase-conjugated goat anti-mouse
IgG and substrate, as described in the text. Concen-
trations of apolipoprotein B in the glycated LDL
preparations were measured by competitive immu-
noassay with the B36 antibody as described in Ma-
terials and Methods. Other non-enzymatically gly-
cated proteins (glycohaemoglobin = closed triangles;
glycoaibumin = open triangles) did not compete for
binding with the ES 12 monoclonal antibody. Non-
glycated LDL (closed squares) and human serum
albumin (open squares) did not compete for binding.
b) Linear dose response curve in the competitive assay
using 10—125 ng per well of glycated LDL in the
soluble phase.
shown) and in competitive ELISA with the ES 12
antibody (fig. 1). In contrast, purified preparations of
other glycated proteins (glycated albumin, glycated
haemoglobin), or of non-glycated LDL or human
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albumin added to the soluble phase, did not inhibit
ES 12 binding to the immobilized glycated LDL (fig.
1), thereby corroborating the specificity of the anti-
body for glycated epitopes residing in the LDL com-
plex. Glycated LDL exhibited an inverse linear dose
response between 10 and 125 ng per well (fig Ib);
plasma samples therefore were assayed at dilutions
expected to yield concentrations within this range.
Estimating that glycated LDL could comprise
1—10% of total apolipoprotein B, which has a nor-
mal range of approximately 0.3 — 1.5 g/1, the concen-
tration of glycated LDL (as glycated apolipoprotein
B equivalents) would be in the range of 3 — 150 mg/1.
Samples were therefore diluted 1 : 16-1 : 20 in assay
buffer before addition of 50 μΐ aliquots to the wells.
Figure 2 presents glycated LDL concentrations, ex-
pressed as mg/1, in 22 non-diabetic and 18 diabetic
specimens. Concentrations ranged from 9 — 26 mg/1
in ηοη-diabeitic and from 20—56 mg/1 in diabetic
samples. The difference between mean values in non-
diabetic and diabetic samples was statistically signif-
icant. Calculated as the fraction (percent) of total
apolipoprotein Β that is glycated, values ranged from
1.9—4.8% in non-diabetic subjects and from 3.2 —
14.8% in diabetic patients (fig. 2). Mean intra-assay
and inter-assay coefficients of variation were 7% and
10%, respectively, in 4 measurements in each of 4
samples.
The samples from diabetic subjects were obtained
from patients with type II diabetes whose therapeutic
regimens had not changed during the three months
before the samples were drawn. Eight were receiving
a single injection of intermedi fe-acting insulin, ten
were receiving an oral hypoglycaemic agent, and none
was performing home-glucose monitoring. Concen-
trations of glycohaemoglobin and glycoalbumin in
samples obtained on the same day as those used for
glycated LDL analysis ranged from 7.7 to 15.0% and
1.1 to 3.7%, respectively, indicating varying degrees
of integrated glycaemic control, as would be antici-
pated in patients on unchanging therapeutic pro-
grammes. In these patients, the correlation (r) value
between glycohaemoglobin and glycoalbumin was
0.86, indicating that integrated glycaemia during the
two weeks before sampling approximated that during
the 2—3 months before sampling; in other words,
patients with elevated glycohaemoglobin also had in-
creased glycoalbumin concentrations, reflecting
chronic and unchanged hyperglycaemia during the
preceding 2 — 10 weeks, whereas patients with normal
glycohaemoglobin also had normal glycoalbumin
concentrations, reflecting stability of glycaemic con-
trol during the preceding 2-10 weeks. Therefore,
correlation of glycated LDL concentrations with these
other indicators of integrated glycaemic control was
sought, on the assumption that ambient glycaemia
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Fig. 2. Glycated LDL concentrations in plasma specimens from
non-diabetic and diabetic subjects. Each point repre-
sents a value from an individual subject, determined in
duplicate. Bars show mean and standard errors in each
group. Non-diabetic versus diabetic, p < 0.05.
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Fig. 3. Correlations between glycohaemoglobin (closed circles;
solid line) or glycoalbumin (open circles; dashed line)
and glycated LDL concentrations in simultaneously
drawn samples taken from diabetic subjects. Glycohae-
moglobin measured by phenylboronate agarose affinity
chromatography (Isolab; Akron, Ohio), with normal,
intermediate and elevated ranges established by the
manufacturer as 6-8%, 10—12% and 14-16%, re-
spectively. Glycoalbumin measured by ELISA (Exocell,
Philadelphia, PA), with upper limit of normal range
established by the manufacturer as 2.4 ± 0,29%. Gly-
cohaemoglobin vs. glycated LDL, r = 0.67; glycoalbu-
min vs. glycated LDL, r = 0.77.
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during the week before sampling (estimated circulat-
ing half-life of LDL is 3 - 5 days (29)) in these subjects
probably approximated that during the preceding
2—10 weeks. Figure 3 illustrates these correlations
with r values of 0.67 between glycohaemoglobin and
glycated LDL concentrations, and 0.77 between gly-
coalbumin and glycated LDL concentrations.
Discussion
In developing an immunoassay for glycated LDL, we
considered it important that the antibodies used in
the assay discriminate between glycated versus non-
glycated or oxidatively modified LDL, that they react
with Amadori products of the glycated protein, and
that they distinguish glycated LDL from other cir-
culating glycated proteins. The desirability of anti-
bodies with these characteristics is clear, since the
much greater plasma concentration of non-glycated
LDL or other glycated protein (e. g. albumin) would
obfuscate results if the antibodies lacked adequate
discrimination. Similarly, cross-reactivity with lipid
oxidation products might confuse the assay results.
Further, the Amadori rearrangement of the conden-
sation reaction between glucose and reactive protein
amino groups is the predominant form in which non-
enzymatically glycated proteins exist in vivo. The
ES 12 monoclonal antibody satisfies these require-
ments, given that it does not react with non-glycated
apolipoprotein B/LDL or with other circulating pro-
teins, whether glycated or not, recognizes glycated
LDL formed in vivo, consistent with the Amadori
product, and does not recognize oxidatively or glyc-
oxidatively modified LDL (25).
Apolipoprotein B is the principal protein of LDL, the
major carrier of plasma cholesterol. Apolipoprotein
B is a complex macromolecule that exists in two
primary forms in human plasma (30, 31), and it is the
protein determinant for the cellular recognition and
uptake of LDL by the LDL receptor (32-35). The
binding of apolipoprotein B to the LDL receptor
results in internalization and degradation of LDL,
promoting the clearance of LDL from the plasma and
regulating intracellular cholesterol handling and bio-
synthesis (36—38). Glycatipn of lysine residues in
apolipoprotein B may compromise receptor-mediated
internalization and catabolism of LDL, thereby in-
terfering with cholesterol homeostasis and contrib-
uting to the pathogenesis of atherosclerosis (1, 4—8,
13,16, 39). Thus, direct assessment of LDL glycation
may have diagnostic and epidemiologic importance
as a bio-marker for atherogenic risk, especially in
diabetic populations. Additionally, the 3 —5 day cir-
culating half-life of LDL (29) suggests that measure-
ment of glycated LDL could provide an objective
index of integrated short-term glycaemic control in
diabetic subjects, although there are reports that gly-
cation can prolong or accelerate LDL clearance (2,
13,15,40,41).
The results presented in this study demonstrate that
plasma glycated LDL concentrations can be specifi-
cally measured by enzyme-linked immunosorbent as-
say using a unique and highly specific monoclonal
antibody that recognizes glycated apolipoprotein B
epitopes in the LDL complex (25). The assay shows
a linear dose response at concentrations between 0.2
and 2.5 mg/1 (10 to 125 ng per 50 μΐ aliquot), encom-
passing the range found in a 50 μΐ aliquot of plasma
diluted 1 :20 for assay (20-60 mg/1; 50-150 ng in
50 μΐ of 1 : 20 dilution). Plasma glycated LDL con-
centrations in diabetic subjects were found to be sig-
nificantly greater than in non-diabetic subjects and,
in patients in whom therapy had remained unchanged
for 2 — 3 months before sampling, showed positive
and significant correlation with glycohaemoglobin
and glycoalbumin concentrations. The amount of gly-
cated LDL determined with this assay, expressed as
percent of total apolipoprotein Β that is glycated, is
consistent with that estimated in previous studies us-
ing phenylboronate agarose affinity chromatography
to separate glycated LDL (42—44).
Previously, measurement of the amount of glycated
LDL has required isolation of the LDL complex
followed by separation of glycated from non-glycated
species with affinity chromatography on phenylbo-
ronate, then determination of the amount of LDL in
the different fractions by gel electrophoresis with den-
sitometric scanning or by immunochemical analysis.
The competitive ELISA described herein does not
require extraction, chromatography, or sample pre-
treatment (other than dilution), and can easily be
completed within two hours. Results are quantitative
and reproducible and confirm that non-enzymatic
glycation of LDL, like that of other circulating pro-
teins, is increased in diabetes with attendant hyper-
glycaemia. The availability of this assay should allow
epidemiologic studies and correlative analyses in di-
abetic populations for assessing the predictive value
and risk for atherosclerotic disease associated with
elevated levels of glycated LDL. Measurement of
glycated LDL could also provide an index of short-
term integrated glycaemia that may prove clinically
useful in the management of diabetes.
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